ODDO BHF Small & MIDCAP MORNING NEWS - 05/25/2021
We are initiating coverage of Quantum Genomics (QG) with an Outperform recommendation and a target price of € 12, which represents upside of € 220%. The company is developing a first-in-class drug candidate called firibastat. The molecule is currently in phase 3 in high blood pressure (HBP) and phase II in heart failure (HF). Based on the Phase 2b results, we believe firibastat offers an attractive risk/reward profile and could become a last-line treatment against refractory hypertens...ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.